174727-36-7Relevant articles and documents
Anticancer and anti-inflammatory activities of 1,8-naphthyridine-3-carboxamide derivatives
Srivastava, Sanjay K.,Jaggi, Manu,Singh, Anu T.,Madan, Alka,Rani, Nidhi,Vishnoi, Manupriya,Agarwal, Shiv K.,Mukherjee, Rama,Burman, Anand C.
, p. 6660 - 6664 (2007)
Several 1,8-naphthyridine-3-carboxamide derivatives (8-23) were synthesized and tested for in vitro cytotoxicity against eight cancer cell lines and a normal cell line. Compound 12 exhibited high cytotoxicity (IC50 = 1.37 μM) in HBL-100 (breast) cell line while compounds 17 (IC50 = 3.7 μM) and 22 (IC50 = 3.0 μM) have shown high cytotoxicity in KB (oral) and SW-620 (colon) cell lines, respectively. The synthesized 1,8-naphthyridine-3-carboxamides were also evaluated for anti-inflammatory and myeloprotective activities, indicated by modulation in cytokine and chemokine levels secreted by dendritic cells.
Synthesis and in vitro antitumor activity of novel naphthyridinone derivatives
Jia, Xue-Dong,Wang, Shuo,Wang, Ming-Hua,Liu, Ming-Liang,Xia, Gui-Min,Liu, Xiu-Jun,Chai, Yun,He, Hong-Wei
supporting information, p. 235 - 239 (2017/01/28)
A series of naphthyridinone derivatives based on 1a (a precursor of Voreloxin) were designed and synthesized. Seven compounds having >70% inhibition against HL60 at 30 μmol/L were further evaluated for their in vitro antitumor activity by SRB assay. Results reveal that thiazol-2-yl and 3-aminomethyl-4-benzyloxyimino-3-methylpyrrolidin-1-yl groups are optimal at the N-1 and C-7 positions of naphthyridinone core, respectively. 10j exhibits broad-spectrum activity (IC50: 100-fold more potent than the two references against eight of these cell lines.
ANTINEOPLASTIC DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF
-
, (2011/10/19)
The disclosure concerns heterobicyclic compounds of general formula (I) and acid addition salts, hydrates and solvates thereof, as well as enantiomers, diastereoisomers and mixtures thereof. Methods for preparing the compounds, pharmaceutical compositions, and methods of treatment also are disclosed.